Immuron Limited
Immuron Limited (IMC.AX) Stock Overview
Explore Immuron Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
16.1M
P/E Ratio
-2.14
EPS (TTM)
$-0.03
ROE
-0.64%
IMC.AX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Immuron Limited (IMC.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 54.97, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.06.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.14 and a market capitalization of 16.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Steven George Lydeamore CPA,
7
62 Lygon Street, Carlton, VIC
1999